Medical School Hannover (MHH)
Hanover, Germany
NCT Number: NCT00701142
The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Hanover, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single intravenous infusion
Other names: RiaSTAP
Single intravenous infusion
Time frame: From administration of Haemocomplettan® P until 24 hours later
Time frame: From administration of Haemocomplettan® P until 24 hours later
Time frame: Last suture of initial surgery to end of ICU stay
Time frame: Last suture of initial surgery to end of hospital stay
Time frame: 45 days post surgery
CSL Behring
Industry
Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03718312
Aneurysm, Aortic Aneurysm
Rouen, France
View Trial DetailsNCT01534819
Aneurysm, Aortic Aneurysm
Birmingham, Alabama, United States
View Trial DetailsNCT02784769
Aneurysm, Aortic Aneurysm
Reims, France
View Trial DetailsNCT05711693
Abnormalities, Multiple, Aneurysm
Paris, France
View Trial Details